Table 3. Univariate and multivariate analysis of factors influencing distant metastasis-free survival (DMFS).
| Factors | No. | Univariate | Multivariate | |||
|---|---|---|---|---|---|---|
| 5-year DMFS | P | HR | 95% CI | P | ||
| Sex | ||||||
| Male | 495 | 87.3% | 0.058 | |||
| Female | 224 | 91.5% | ||||
| KPS | ||||||
| ≥ 90 | 694 | 90.3% | 0.523 | |||
| < 90 | 25 | 87.2% | ||||
| Age (years) | ||||||
| < 50 | 382 | 89.7% | 0.645 | |||
| ≥ 50 | 337 | 90.1% | ||||
| Therapy | ||||||
| CCRT | 698 | 90.4% | 0.704 | |||
| RT alone | 21 | 83.8% | ||||
| Induced CT | ||||||
| Yes | 649 | 90.0% | 0.386 | |||
| No | 70 | 93.9% | ||||
| Adjuvant CT | ||||||
| Yes | 183 | 86.4% | 0.307 | |||
| No | 536 | 91.2% | ||||
| LDH (IU/L) | ||||||
| < 187 | 500 | 89.8% | 0.271 | |||
| ≥ 187 | 218 | 92.0% | ||||
| CD4+ T cells (%) | ||||||
| < 32.5 | 266 | 82.3% | < 0.001 | |||
| ≥ 32.5 | 453 | 92.7% | ||||
| CD8+ T cells (%) | ||||||
| < 19.5 | 411 | 91.5% | 0.098 | |||
| ≥ 19.5 | 308 | 88.8% | ||||
| CD44+ T cells (%) | ||||||
| < 65.5 | 158 | 93.3% | 0.187 | |||
| ≥ 65.5 | 561 | 89.7% | ||||
| NK cell (%) | ||||||
| < 12.5 | 85 | 85.4% | 0.050 | 0.554 | 0.293 - 1.049 | 0.070 |
| ≥ 12.5 | 634 | 89.6% | ||||
| CD4/CD8 ratio | ||||||
| < 1.77 | 295 | 85.4% | < 0.001 | 0.450 | 0.266 - 0.760 | 0.003 |
| ≥ 1.77 | 424 | 91.9% | ||||
| T stage* | ||||||
| T 1-2 | 180 | 91.7% | 0.052 | |||
| T 3-4 | 539 | 88.7% | ||||
| N stage* | ||||||
| N 0-1 | 446 | 93.2% | 0.001 | 2.294 | 1.370 - 3.839 | 0.002 |
| N 2-3 | 273 | 83.1% | ||||
KPS, Karnofsky performance scale; LDH, lactic dehydrogenase; CI, confidence interval; HR, hazard ration; SD, standard deviation; CCRT, Concurrent Chemoradiotherapy; RT: radiotherapy; CT, chemotherapy.
*
According to the 7th AJCC/International Union against Cancer staging system.